ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

NSCLC Experts Ponder Best First-Line Treatment Options

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies

The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.

Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.

Russ Conroy

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.

Related Content

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Paolo Tarantino, MD;Matteo Lambertini, MD

January 13th 2025

NSCLC Experts Ponder Best First-Line Treatment Options

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD

January 6th 2025

Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies

The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.

Russ Conroy